Targeting renal cell carcinoma with a HIF-2 antagonist.

doi:10.1038/nature19796

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting renal cell carcinoma with a HIF-2 antagonist.

Nature - 3 Nov 2016

Chen Wenfang, Hill Haley, Christie Alana, Kim Min Soo, Holloman Eboni, Pavia-Jimenez Andrea, Homayoun Farrah, Ma Yuanqing, Patel Nirav, Yell Paul, Hao Guiyang, Yousuf Qurratulain, Joyce Allison, Pedrosa Ivan, Geiger Heather, Zhang He, Chang Jenny, Gardner Kevin H, Bruick Richard K, Reeves Catherine, Hwang Tae Hyun, Courtney Kevin, Frenkel Eugene, Sun Xiankai, Zojwalla Naseem, Wong Tai, Rizzi James P, Wallace Eli M, Josey John A, Xie Yang, Xie Xian-Jin, Kapur Payal, McKay Renée M, Brugarolas James

Abstract excerpt

Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL). Because no other gene is mutated as frequently in ccRCC and VHL mutations are truncal, VHL inactivation is regarded as the governing event. VHL loss activates the HIF-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Receptor Nuclear Translocator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Erythropoietin

Share to Indans

Share to Mice, Inbred NOD

Share to Pyrroles

Share to Sulfones

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 27595394
DOI: 10.1038/nature19796
PMCID: PMC5340502

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-27595394-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting renal cell carcinoma with a HIF-2 antagonist.PMID 27595394Read ↗

Differential Effects of HIF2α Antagonist and HIF2α Silencing in Renal Cancer and Sensitivity to Repurposed DrugsSemantic proximity Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal CancerSemantic proximity Read ↗

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.Semantic proximity Read ↗

Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathwaySemantic proximity Read ↗

HIF2a regulates ccRCC tumorigenesis through activation of cell cycle regulatorsSemantic proximity Read ↗

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in miceSemantic proximity Read ↗

Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discoverySemantic proximity Read ↗

VHL and HIF signalling in renal cell carcinogenesisSemantic proximity Read ↗

Current Landscape and the Potential Role of HIF and Selenium in Clear Cell Renal Cell Carcinoma TreatmentSemantic proximity Read ↗

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Neuropilin 1 and Neuropilin 2 Gene Invalidation or Pharmacological Inhibition Reveals Their Relevance for the Treatment of Metastatic Renal Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.